Compare CHR & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | FATE |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.9M | 139.6M |
| IPO Year | N/A | 2013 |
| Metric | CHR | FATE |
|---|---|---|
| Price | $1.44 | $1.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | 151.9K | ★ 1.8M |
| Earning Date | 07-30-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 96.06 | N/A |
| Revenue | ★ $147,134,000.00 | $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $0.66 |
| 52 Week High | $141.71 | $1.94 |
| Indicator | CHR | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 53.37 |
| Support Level | $1.48 | $1.17 |
| Resistance Level | $1.63 | $1.32 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 3.93 | 51.67 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerReal, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.